These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

600 related items for PubMed ID: 16167412

  • 1. Biologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-cell-targeted therapies efalizumab and alefacept.
    Weinberg JM, Bottino CJ, Lindholm J, Buchholz R.
    J Drugs Dermatol; 2005; 4(5):544-55. PubMed ID: 16167412
    [Abstract] [Full Text] [Related]

  • 2. Advances in therapy for psoriasis: an overview of infliximab, etanercept, efalizumab, alefacept, adalimumab, tazarotene, and pimecrolimus.
    Saini R, Tutrone WD, Weinberg JM.
    Curr Pharm Des; 2005; 11(2):273-80. PubMed ID: 15638763
    [Abstract] [Full Text] [Related]

  • 3. Biological therapy for psoriasis: an overview of infliximab, etanercept, efalizumab and alefacept.
    Tutrone WD, Saini R, Weinberg JM.
    IDrugs; 2004 Jan; 7(1):45-9. PubMed ID: 14730466
    [Abstract] [Full Text] [Related]

  • 4. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis.
    Weinberg JM.
    Clin Ther; 2003 Oct; 25(10):2487-505. PubMed ID: 14667953
    [Abstract] [Full Text] [Related]

  • 5. Biologic therapy for psoriasis--the first wave: infliximab, etanercept, efalizumab, and alefacept.
    Weinberg JM, Saini R, Tutrone WD.
    J Drugs Dermatol; 2002 Dec; 1(3):303-10. PubMed ID: 12851990
    [Abstract] [Full Text] [Related]

  • 6. Biologic therapy for psoriasis: the tumor necrosis factor inhibitors infliximab and etanercept.
    Weinberg JM, Saini R.
    Cutis; 2003 Jan; 71(1):25-9. PubMed ID: 12553627
    [Abstract] [Full Text] [Related]

  • 7. New biologic therapies for psoriatic disease.
    Bohjanen KA, Prawer SE.
    Minn Med; 2004 Mar; 87(3):34-6. PubMed ID: 15080292
    [Abstract] [Full Text] [Related]

  • 8. Biologic therapeutics in the treatment of psoriasis. Part 1: review.
    Langley RG, Gupta AK, Cherman AM, Inniss KA.
    J Cutan Med Surg; 2007 Mar; 11(3):99-122. PubMed ID: 17511926
    [Abstract] [Full Text] [Related]

  • 9. Biological agents in the treatment of psoriasis.
    Tzu J, Krulig E, Cardenas V, Kerdel FA.
    G Ital Dermatol Venereol; 2008 Oct; 143(5):315-27. PubMed ID: 18833073
    [Abstract] [Full Text] [Related]

  • 10. [New systemic treatments for psoriasis: etanercept, infliximab, adalimumab, efalizumab and alefacept].
    Bos WE, Thio HB, Neumann HA, van der Fits L, Prens EP.
    Ned Tijdschr Geneeskd; 2006 May 13; 150(19):1065-70. PubMed ID: 16733982
    [Abstract] [Full Text] [Related]

  • 11. Adverse reactions during biological drug therapy in psoriasis:clinical series and a review of the literature.
    Montesu MA, Addis GM, Satta R, Cottoni F.
    G Ital Dermatol Venereol; 2011 Aug 13; 146(4):273-81. PubMed ID: 21785393
    [Abstract] [Full Text] [Related]

  • 12. Update on the mechanisms and efficacy of biological therapies for psoriasis.
    Koo J, Khera P.
    J Dermatol Sci; 2005 May 13; 38(2):75-87. PubMed ID: 15862940
    [Abstract] [Full Text] [Related]

  • 13. Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2).
    Graves JE, Nunley K, Heffernan MP.
    J Am Acad Dermatol; 2007 Jan 13; 56(1):e55-79. PubMed ID: 17190618
    [Abstract] [Full Text] [Related]

  • 14. Biologic therapies for psoriasis. A systematic review.
    Boehncke WH, Prinz J, Gottlieb AB.
    J Rheumatol; 2006 Jul 13; 33(7):1447-51. PubMed ID: 16724367
    [Abstract] [Full Text] [Related]

  • 15. Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States.
    Anis AH, Bansback N, Sizto S, Gupta SR, Willian MK, Feldman SR.
    J Dermatolog Treat; 2011 Apr 13; 22(2):65-74. PubMed ID: 20443663
    [Abstract] [Full Text] [Related]

  • 16. Biologic therapy for psoriasis: the T-cell-targeted therapies efalizumab and alefacept.
    Weinberg JM, Tutrone WD.
    Cutis; 2003 Jan 13; 71(1):41-5. PubMed ID: 12553629
    [Abstract] [Full Text] [Related]

  • 17. Biologicals in the treatment of psoriasis.
    Boker A, Kimball AB, Rolz-Cruz G.
    Curr Opin Investig Drugs; 2007 Nov 13; 8(11):939-46. PubMed ID: 17979028
    [Abstract] [Full Text] [Related]

  • 18. Immunobiologics in the treatment of psoriasis.
    Chong BF, Wong HK.
    Clin Immunol; 2007 May 13; 123(2):129-38. PubMed ID: 17317321
    [Abstract] [Full Text] [Related]

  • 19. Cost effectiveness of biologic therapies for plaque psoriasis.
    Ahn CS, Gustafson CJ, Sandoval LF, Davis SA, Feldman SR.
    Am J Clin Dermatol; 2013 Aug 13; 14(4):315-26. PubMed ID: 23696234
    [Abstract] [Full Text] [Related]

  • 20. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials.
    Brimhall AK, King LN, Licciardone JC, Jacobe H, Menter A.
    Br J Dermatol; 2008 Aug 13; 159(2):274-85. PubMed ID: 18547300
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.